tetrabenazine has been researched along with Neurodegenerative Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altavilla, R; Arosio, C; di Biase, L; Frontali, M; Marano, M; Melgari, JM; Nuovo, S; Piperno, A; Quattrocchi, CC; Salomone, G; Scrascia, F; Siotto, M; Squitti, R; Vernieri, F | 1 |
| Albin, RL; Bohnen, NI; Davatzikos, C; Foerster, BR; Frey, KA; Herman, WH; Hsieh, M; Koeppe, RA; Kotagal, V; Müller, ML; Petrou, M | 1 |
2 other study(ies) available for tetrabenazine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Movement disorders and brain iron overload in a new subtype of aceruloplasminemia.
Topics: Adrenergic Uptake Inhibitors; Brain; Ceruloplasmin; Chorea; Diagnosis, Differential; Dystonia; Female; Humans; Iron Metabolism Disorders; Iron Overload; Middle Aged; Movement Disorders; Neurodegenerative Diseases; Tetrabenazine; Treatment Outcome | 2015 |
Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease.
Topics: Aged; Atrophy; Attention; Basal Ganglia; Brain Diseases; Carbon Radioisotopes; Case-Control Studies; Cognition; Cross-Sectional Studies; Diabetes Complications; Dopaminergic Neurons; Executive Function; Female; Frontal Lobe; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurodegenerative Diseases; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tetrabenazine | 2016 |